Literature DB >> 2172467

Endogenous benzodiazepine receptor ligands in human and animal hepatic encephalopathy.

M Olasmaa1, J D Rothstein, A Guidotti, R J Weber, S M Paul, S Spector, M L Zeneroli, M Baraldi, E Costa.   

Abstract

The role of endogenous benzodiazepine receptor ligands in the pathogenesis of hepatic encephalopathy was studied in humans and in rat models of hepatic encephalopathy. Endogenous benzodiazepine ligands were extracted from rat brain and human CSF by acid treatment and purification by HPLC. Detection and partial characterization of these endogenous benzodiazepine ligands were carried out using both radioreceptor binding assays and radioimmunoassays with anti-benzodiazepine antibodies. Four different benzodiazepine receptor ligands were identified in human and rat tissue, two of which may be diazepam and desmethyldiazepam, based on elution profiles and anti-benzo-diazepine antibody reactivity. Human CSF and serum from patients with hepatic encephalopathy contained approximately 10 times more endogenous benzodiazepine receptor ligand than CSF from controls or nonencephalopathic patients with liver disease. The levels of brain benzodiazepine receptor ligand compounds were also increased approximately 10-fold in rats suffering from fulminant hepatic failure, but not in rats with portacaval shunts, a model of chronic hepatic disease. The increased concentrations of these substances could be behaviorally significant and may contribute to the pathogenesis of hepatic encephalopathy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2172467     DOI: 10.1111/j.1471-4159.1990.tb05790.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  24 in total

Review 1.  Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management.

Authors:  T Gerber; H Schomerus
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 2.  Pathogenesis and treatment of portal-systemic encephalopathy: an update.

Authors:  R F Butterworth
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

Review 3.  Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure?

Authors:  E A Jones; A S Basile
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

4.  Current concepts in the pathophysiology and management of hepatic encephalopathy.

Authors:  R Todd Frederick
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-04

5.  Neuroactive amino acids in hepatic encephalopathy.

Authors:  R F Butterworth
Journal:  Metab Brain Dis       Date:  1996-06       Impact factor: 3.584

6.  Benzodiazepine-insensitive mice generated by targeted disruption of the gamma 2 subunit gene of gamma-aminobutyric acid type A receptors.

Authors:  U Günther; J Benson; D Benke; J M Fritschy; G Reyes; F Knoflach; F Crestani; A Aguzzi; M Arigoni; Y Lang; H Bluethmann; H Mohler; B Lüscher
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

7.  Cognitive impairments of alcoholic cirrhotic patients: correlation with endogenous benzodiazepine receptor ligands and increased affinity of platelet receptors.

Authors:  F Kapczinski; H V Curran; R Przemioslo; R Williams; E Fluck; C Fernandes; S E File
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

Review 8.  Neuropsychological aspects of liver disease and its treatment.

Authors:  R E O'Carroll
Journal:  Neurochem Res       Date:  2007-10-24       Impact factor: 3.996

Review 9.  Benzodiazepines in the brain. Their origin and possible biological roles.

Authors:  J H Medina; C Peña; M Piva; C Wolfman; M L de Stein; C Wasowski; C Da Cunha; I Izquierdo; A C Paladini
Journal:  Mol Neurobiol       Date:  1992       Impact factor: 5.590

10.  Benzodiazepine-like substances and hepatic encephalopathy : implications for treatment.

Authors:  J A Cossar; P C Hayes; R E O'Carroll
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.